Record-breaking pharma M&A value disguises plummeting deal-making activity
Abundant biotech funding seems to be empowering small- and medium-sized IP rights holders and driving down acquisition and licensing volume
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now